What Is Immune Checkpoint Therapy?

The immune system is remarkably powerful — but cancer has evolved clever ways to hide from it. Checkpoint inhibitors are a class of immunotherapy drugs designed to remove the "brakes" that cancer puts on immune cells, allowing the body's own defenses to recognize and destroy tumors. This approach has revolutionized oncology over the past decade and is now a standard treatment for several cancer types.

Understanding Immune Checkpoints

Immune checkpoints are regulatory proteins on the surface of T cells (and other immune cells) that normally prevent the immune system from attacking healthy tissue. Think of them as safety switches. Cancer cells exploit these checkpoints to disguise themselves as normal tissue and avoid destruction.

The three most clinically important checkpoints targeted by current drugs are:

  • PD-1 (Programmed Death-1): A receptor on T cells. When PD-1 binds to PD-L1 on cancer cells, the T cell is essentially "switched off."
  • PD-L1 (Programmed Death Ligand-1): The protein expressed on tumor cells that binds PD-1, suppressing immune activity.
  • CTLA-4: Another T cell receptor that downregulates immune activation at an earlier stage than PD-1.

How Checkpoint Inhibitors Work

Checkpoint inhibitor drugs are monoclonal antibodies engineered to block these interactions. By blocking PD-1 or CTLA-4 on T cells — or blocking PD-L1 on tumor cells — these drugs restore the immune system's ability to recognize and attack cancer.

Approved Checkpoint Inhibitor Drugs

Drug (Generic Name) Target Common Brand Name
Pembrolizumab PD-1 Keytruda
Nivolumab PD-1 Opdivo
Atezolizumab PD-L1 Tecentriq
Durvalumab PD-L1 Imfinzi
Ipilimumab CTLA-4 Yervoy

Which Cancers Are Treated with Checkpoint Inhibitors?

Checkpoint inhibitors have received FDA approval for a wide and growing range of cancers, including:

  • Non-small cell lung cancer (NSCLC)
  • Melanoma
  • Renal cell carcinoma (kidney cancer)
  • Bladder/urothelial carcinoma
  • Head and neck squamous cell carcinoma
  • Triple-negative breast cancer
  • Certain colorectal cancers (MSI-H/dMMR)
  • Hodgkin lymphoma

Biomarker Testing: Who Responds Best?

Not everyone responds equally to checkpoint inhibitors. Oncologists use several biomarkers to predict response:

  • PD-L1 expression level: Higher expression often correlates with better response to PD-1/PD-L1 blockers.
  • Tumor Mutational Burden (TMB): Tumors with more mutations may generate more recognizable antigens for the immune system.
  • MSI-H/dMMR status: Microsatellite instability-high tumors tend to respond well regardless of cancer type.

Important Considerations

Checkpoint inhibitors can cause immune-related adverse events (irAEs) — inflammation in healthy organs including the lungs, liver, colon, and endocrine glands. These range from mild to severe and require careful monitoring. Patients should report any new symptoms promptly to their care team.

Dual checkpoint blockade (e.g., combining nivolumab and ipilimumab) can enhance efficacy but also increases the risk of immune-related side effects.